| Information About Albumin Therapy | What Is Albumin?

What is Albumin?

Human albumin is an essential protein found in human plasma and accounts for about 50%-60% of plasma proteins.1 Each molecule is composed of three units, or domains, which function together to give albumin its unique binding properties.3 It is the primary agent responsible for maintaining osmotic pressure of the blood, and for transport of fatty acids, hormones, enzymes, and therapeutic drugs.2

Albumin is primarily responsible for 75%-80% of plasma's normal colloid oncotic pressure.1 Albumin supplementation restores intravascular volume and maintains cardiac output and colloid osmotic pressure. When plasma volume is drastically reduced, albumin can help restore the losses.1

FLEXBUMIN 25% [Albumin (Human)]

FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration.  FLEXBUMIN 25% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns, adult respiratory distress syndrome (ARDS), and nephrosis, and for use during or prior to cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).

Important Risk Information for FLEXBUMIN 25%

FLEXBUMIN 25% is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.

Do not use if turbid.  Do not begin administration more than 4 hours after the container has been entered.

Do not use Sterile Water for Injection as a diluent. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for FLEXBUMIN 25%.  Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water.

FLEXBUMIN 25% is made from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt–Jakob disease (CJD) agent.

FLEXBUMIN 25% must be administered intravenously at a rate not to exceed 1 mL/min to patients with normal blood volume, due to the risk of developing circulatory overload and pulmonary edema. 

When 25% albumin is infused, a rise in blood pressure necessitates careful observation to detect and treat severed blood vessels that may not have bled at a lower blood pressure.  

Adverse reactions to FLEXBUMIN 25% are extremely rare, although nausea, fever, chills or urticaria may occasionally occur.

CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

Please see Preparation for Administration for FLEXBUMIN 25% in the Prescribing Information.

Please review the FLEXBUMIN 25% [Albumin (Human)] Prescribing Information for full prescribing details.

Please see detailed Important Risk Information for BUMINATE 5% and Full Prescribing Information.

Please see detailed Important Risk Information for BUMINATE 25% and Full Prescribing Information.

  1. Gonzalez ER, Kannewurf BS. Clinical review of appropriate uses for albumin. US Pharmacist. 1998;23:HS15-HS26.
  2. Peters T Jr. Serum albumin. In: Putnam FW, ed. The Plasma Proteins. 2nd ed. New York, NY: Academic Press; 1975;133-181.
  3. Doweiko JP, Nompleggi DJ. Role of albumin in human physiology and pathology. Journal of Parenteral and Enteral Nutrition. 1991;15:207-211.
Back to top.

FLEXBUMIN 25% [Albumin (Human)],
25% Solution

Image of Flexbumin container.
The first and only formulation of human albumin available in a flexible container.
More >